Skip to content

Study · Not a test of the peptide alone · 2017

2 results

Combination of PTH (1-34) with anti-IL17 prevents bone loss by inhibiting IL-17/N-cadherin mediated disruption of PTHR1/LRP-6 interaction.

Mansoori MN, Shukla P, Singh D

Bone19 Sept 2017Cited by 21 (Europe PMC)

PMID28935557 (opens in a new tab)DOI10.1016/j.bone.2017.09.010 (opens in a new tab)PepBankPUB-28935557
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 01AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome

    In ovariectomized mice, combined iPTH and anti-IL17 restored skeletal and immune parameters synergistically compared with monotherapies.

    In plain wordsIn mice, combined iPTH and anti-IL17 restored skeletal and immune parameters more than monotherapies.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSkeletal and immune parameter restoration
    Study

    mousen: not reported in source

    Ovariectomized BALB/c female mice
    Comparator
    Monotherapies
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Combination of iPTH and anti-IL17 has synergistic effect in the restoration of skeletal and immune parameters compared to mono-therapies.
    1 context sentence
    Summary · context
    Ovariectomized BALB/c female mice were treated with anti-IL17 and iPTH monotherapies and their combination.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 02AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Mechanism

    In ovariectomized mice, bone sections treated with iPTH plus anti-IL17 showed decreased PTHR1 expression.

    In plain wordsIn mice, bone sections treated with iPTH plus anti-IL17 showed decreased PTHR1 expression.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreasePTHR1 expression
    Study

    mousen: not reported in source

    Ovariectomized BALB/c female mice
    Outcome group
    Receptor activity and mechanism · Musculoskeletal

    Source sentences

    Summary
    Immunofluorescence analysis shows decreased expression of PTHR1 in iPTH+anti-IL17 treated bone sections.
    1 context sentence
    Summary · context
    Ovariectomized BALB/c female mice were treated with anti-IL17 and iPTH monotherapies and their combination.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.